Abstract
Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality?
Highlights
The majority of enhancing renal masses are unable to be effectively characterized as benign or malignant using standard cross-sectional imaging modalities including multi-phase computed tomography (CT) [1] and magnetic resonance imaging (MRI) [2]
Several reports have been published on the ability of 99mTc-sestamibi planar and single photon emission computed tomography (SPECT)/CT imaging to differentiate mitochondrial-rich benign and indolent renal masses such as oncocytomas and hybrid oncocytic/ chromophobe tumors (HOCTs) from more aggressive renal tumor histologies including the clear cell subtype of renal cell carcinoma (RCC) [8,9,10]
The work of Tzortzakakis and coworkers [11] is a critical step in laying the foundation for the widespread use of molecular imaging for renal mass characterization, further efforts would be of value for advancing the field to the point of routine clinical application
Summary
The majority of enhancing renal masses are unable to be effectively characterized as benign or malignant using standard cross-sectional imaging modalities including multi-phase computed tomography (CT) [1] and magnetic resonance imaging (MRI) [2]. Several reports have been published on the ability of 99mTc-sestamibi planar and single photon emission computed tomography (SPECT)/CT imaging to differentiate mitochondrial-rich benign and indolent renal masses such as oncocytomas and hybrid oncocytic/ chromophobe tumors (HOCTs) from more aggressive renal tumor histologies including the clear cell subtype of renal cell carcinoma (RCC) [8,9,10].
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call